{
  "id": "cf00bf2c5eb6774b",
  "title": "FDA Approves Aficamten ( Myqorzo ) for Symptomatic Obstructive Hypertrophic Cardiomyopathy",
  "description": "20251219T220000Z",
  "content": "",
  "source": "hcplive.com",
  "source_url": "https://www.hcplive.com/view/fda-approves-aficamten-myqorzo-for-symptomatic-obstructive-hypertrophic-cardiomyopathy",
  "published_at": "20251219T220000Z",
  "fetched_at": "2025-12-20T00:22:03.659749+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.hcplive.com/view/fda-approves-aficamten-myqorzo-for-symptomatic-obstructive-hypertrophic-cardiomyopathy",
    "url_mobile": "",
    "title": "FDA Approves Aficamten ( Myqorzo ) for Symptomatic Obstructive Hypertrophic Cardiomyopathy",
    "seendate": "20251219T220000Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/hcplive/8c9fc7db85bab8d7795d7e7f3fe25112d090c457-400x400.webp",
    "domain": "hcplive.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}